Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ: ARCT )

26.19 -0.79 (-2.93%)
Streaming Delayed Price Updated: 12:43 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 142,196
Open 26.09
Bid (Size) 26.14 (2)
Ask (Size) 26.22 (2)
Prev. Close 26.98
Today's Range 25.41 - 26.36
52wk Range 17.52 - 43.81
Shares Outstanding 26,562,951
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The Analyst Verdict: Arcturus Therapeutics In The Eyes Of 4 Experts
Via Benzinga
ARCT Stock Earnings: Arcturus Therapeutics Beats EPS, Misses Revenue for Q4 2023
ARCT stock results show that Arcturus Therapeutics beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-20.85%
-20.85%
1 Month
-24.72%
-24.72%
3 Month
-18.66%
-18.66%
6 Month
+38.35%
+38.35%
1 Year
-6.73%
-6.73%

More News

Read More
Recap: Arcturus Therapeutics Q4 Earnings
Via Benzinga
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Evaluating NASDAQ:ARCT for Growth Investment Opportunities.
Via Chartmill
Is NASDAQ:ARCT suited for growth investing?
Via Chartmill
Earnings Scheduled For March 7, 2024
Via Benzinga
Earnings Preview: Arcturus Therapeutics
Via Benzinga
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Via InvestorPlace
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024
Via InvestorPlace
3 Tech Stocks That Could Be Multibaggers in the Making: February Edition
Via InvestorPlace
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
Logitech Posts Q3 Results, Joins Coinbase And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Why the growth investor may take a look at ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT).
Via Chartmill
ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) showing high EPS and FCF growth while beating expectations
Via Chartmill
CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
From Arcturus Therapeutics
Via Business Wire
7 Undervalued Biotech Stocks That are Flying Under the Clinical Radar
Via InvestorPlace
3 Biotech Stocks With Promising Pipelines and Big Growth Potential in 2024
Via InvestorPlace
Arcturus Therapeutics' Lung Disease Candidate Triggers Bullish Rating, Analyst Sees Over 200% Upside
Via Benzinga
5 Value Stocks In The Healthcare Sector
Via Benzinga
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Why the growth investor may take a look at NASDAQ:ARCT.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.